Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
PGF-H52G3 | Human | Human PLGF / PGF (19-149) Protein, GST Tag | ![]() |
||
PGF-H5255 | Human | Human PLGF / PGF (19-221) Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
PGF-H5256 | Human | Human PLGF / PGF (19-149) Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
PGF-H52H5 | Human | Human PLGF / PGF (19-149) Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
PGF-H52H4 | Human | Human PLGF / PGF (19-221) Protein, His Tag | ![]() |
||
PGF-M52H0 | Mouse | Mouse PLGF / PGF Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
PGF-R52H0 | Rhesus macaque | Rhesus macaque PLGF / PGF Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
PGF-H5229 | Human | Human PLGF / PGF Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human VEGF R1, His Tag (Cat. No. VE1-H5220) at 2 μg/mL (100 μL/well) can bind Human PLGF (19-149), Fc Tag (Cat. No. PGF-H5256) with a linear range of 0.6-5 ng/mL (QC tested).
The purity of Human PLGF (19-221), Fc Tag (Cat. No. PGF-H5255) was more than 85% and the molecular weight of this protein is around 115-130 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Aflibercept | BAY-865321; BAT-86-5321 | Approved | Regeneron Pharmaceutical, Bayer, Santen | EYLEA | fda | Macular edema, Macular degeneration | REGENERON PHARMACEUTICALS | 2011-11-18 | Macular edema, Macular degeneration | Details |
Ziv-aflibercept | AVE-0005; BAY-865321 | Approved | Regeneron Pharmaceutical, Sanofi, Yakult | ZALTRAP | fda | Metastatic colorectal cancer (CRC) | SANOFI AVENTIS US | 2012-08-03 | Colorectal cancer, Metastatic colorectal cancer (CRC) | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012 | Phase Ⅰ | Shandong Boan Biotechnology, Luye Pharma | Metastatic colorectal cancer (CRC) | Details |
Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Phase Ⅲ | Momenta, Mylan | Diabetic macular edema | Details |
Aflibercept biosimilar (Samsung Bioepis) | SB-15 | Phase Ⅲ | Samsung Bioepis | Wet age-related macular degeneration | Details |
Aflibercept biosimilar (CinnaGen)(阿柏西普生物类似药(CinnaGen)) | Phase Ⅲ | CinnaGen | Wet age-related macular degeneration | Details | |
Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Phase Ⅲ | Qilu Pharmaceutical | Diabetic macular edema, Wet age-related macular degeneration | Details |
Aflibercept Biosimilar (Boan Biopharma/Luye) | LY-09004 | Phase Ⅰ | Shandong Boan Biotechnology, Luye Pharma | Diabetic macular edema, Senile Macular Degeneration | Details |
Aflibercept/Rinucumab | REGN-2176-3 | Phase Ⅱ | Bayer, Regeneron Pharmaceutical | Wet age-related macular degeneration | Details |
Aflibercept biosimilar (Amgen) | Phase Ⅱ | Amgen | Wet age-related macular degeneration | Details | |
Aflibercept/Nesvacumab | REGN 910-3 | Phase Ⅱ | Regeneron Pharmaceutical, Bayer | Diabetic macular edema, Wet age-related macular degeneration | Details |
Anti-placental growth factor monoclonal antibody | R-7334; RG-7334; RO-5323441; TB-403; THR-317; αPlGF | Phase Ⅱ | BioInvent International, ThromboGenics, Roche, Oncurious | Age-related macular degeneration (AMD), Medulloblastoma | Details |
This web search service is supported by Google Inc.